Capital Advisors Inc. OK Grows Stock Position in Medtronic PLC $MDT

Capital Advisors Inc. OK lifted its holdings in Medtronic PLC (NYSE:MDT) by 8.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 639,288 shares of the medical technology company’s stock after purchasing an additional 49,060 shares during the period. Capital Advisors Inc. OK’s holdings in Medtronic were worth $61,410,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Barclays PLC raised its holdings in Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock worth $650,604,000 after purchasing an additional 3,492,192 shares during the period. Schroder Investment Management Group grew its holdings in Medtronic by 78.3% during the third quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after purchasing an additional 3,307,211 shares during the period. Guinness Asset Management LTD purchased a new stake in Medtronic in the third quarter worth about $275,556,000. Wellington Management Group LLP increased its position in Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after buying an additional 2,658,981 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Medtronic by 2,297.7% in the fourth quarter. SG Americas Securities LLC now owns 2,510,712 shares of the medical technology company’s stock worth $241,179,000 after buying an additional 2,406,000 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.0%

MDT stock opened at $86.57 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The business has a 50 day simple moving average of $95.34 and a two-hundred day simple moving average of $96.41. The company has a market capitalization of $111.15 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 2.21 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter last year, the business posted $1.38 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s payout ratio is presently 79.11%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on MDT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price objective on shares of Medtronic in a research report on Thursday, March 26th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday. Barclays reissued an “overweight” rating and issued a $118.00 price objective on shares of Medtronic in a research note on Wednesday, February 18th. Wells Fargo & Company assumed coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 target price on the stock. Finally, UBS Group reaffirmed a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).